Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.32 |
| ▸ | TKT | P29401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494744 | 0.84 | LTB4R (0.38) | MEN1KMT2ALTB4R | |
| SCHEMBL2690986 | 0.75 | — | — | |
| SCHEMBL5109192 | 0.75 | LTB4R (0.34) | LTB4R | |
| SCHEMBL4512133 | 0.73 | MEN1 (0.38) | MEN1KMT2ATKT | |
| SCHEMBL4501241 | 0.73 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL4511710 | 0.73 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL4743163 | 0.70 | HTR2A (0.46) | LTB4R | |
| SCHEMBL11215124 | 0.69 | — | — | |
| SCHEMBL2223496 | 0.69 | LIPG (0.43) | MEN1KMT2ALTB4R | |
| SCHEMBL27939540 | 0.68 | MEN1 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | MEN1 4619/4885KMT2A 4609/4885LTB4R 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.